Back to GetFilings.com



Table of Contents



UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

     
þ   QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
    For the quarterly period ended June 30, 2003
 
o
  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
    For the transition period from           to

Commission file number 000-29273

QUOVADX, INC.

(Exact name of registrant as specified in its charter)
     
Delaware   85-0373486
(State or other jurisdiction of
incorporation or organization)
  (I.R.S. Employer
Identification No.)

6400 S. Fiddler’s Green Circle, Suite 1000, Englewood, Colorado 80111

(Address of principal executive offices)

(303) 488-2019

(Registrant’s telephone number)

     Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     Yes þ          No o

      Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act).     Yes þ          No o

      At August 4, 2003, 30,537,391 shares of common stock were outstanding.




TABLE OF CONTENTS

PART I FINANCIAL INFORMATION
Item 1. Condensed Consolidated Financial Statements
CONDENSED CONSOLIDATED BALANCE SHEETS
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
FORWARD-LOOKING STATEMENTS
RISK FACTORS
Item 3. Quantitative and Qualitative Disclosures About Market Risk
Item 4. Controls and Procedures
PART II OTHER INFORMATION
Item 1. Legal Proceedings
Item 2. Changes in Securities and Use of Proceeds
Item 3. Defaults Upon Senior Securities
Item 4. Submission of Matters to a Vote of Security Holders
Item 5. Other Information
Item 6. Exhibits and Reports on Form 8-K
SIGNATURES
EX-31.1 Certification of Chief Executive Officer
EX-31.2 Certification of Chief Financial Officer
EX-32.1 Certification of Chief Executive Officer
EX-32.2 Certification of Chief Financial Officer


Table of Contents

QUOVADX, INC.

TABLE OF CONTENTS

           
Page No.

Part I — Financial Information
       
 
Item 1 — Condensed Consolidated Financial Statements:
       
Condensed Consolidated Balance Sheets as of June 30, 2003 and December 31, 2002
    3  
Condensed Consolidated Statements of Operations for the three months and six months ended June 30, 2003 and 2002
    4  
Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2003 and 2002
    5  
Notes to Condensed Consolidated Financial Statements
    6  
 
Item 2 — Management’s Discussion and Analysis of Financial Condition and Results of Operations
    9  
 
Item 3 — Quantitative and Qualitative Disclosures About Market Risk
    19  
 
Item 4 — Controls and Procedures
    19  
Part II — Other Information
       
 
Item 1 — Legal Proceedings
    20  
 
Item 2 — Changes in Securities and Use of Proceeds
    21  
 
Item 3 — Defaults Upon Senior Securities
    21  
 
Item 4 — Submission of Matters to a Vote of Security Holders
    21  
 
Item 5 — Other Information
    21  
 
Item 6 — Exhibits and Reports on Form 8-K
    21  
Signatures
    22  

2


Table of Contents

PART I FINANCIAL INFORMATION

 
Item 1.      Condensed Consolidated Financial Statements

QUOVADX, INC.

 
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except for share and per share amounts)
(Unaudited)
                       
June 30, December 31,
2003 2002


ASSETS
Current assets:
               
 
Cash and cash equivalents
  $ 36,600     $ 31,244  
 
Short-term investments
    5,491       16,377  
 
Accounts receivable, net of allowance of $2,037 and $2,370, respectively
    8,762       10,980  
 
Unbilled accounts receivable
    8,037       5,571  
 
Other current assets
    3,506       1,904  
     
     
 
   
Total current assets
    62,396       66,076  
Property and equipment, net
    4,680       5,326  
Software, net
    18,901       20,465  
Other intangible assets, net
    5,502       6,266  
Other assets
    6,095       6,476  
     
     
 
   
Total assets
  $ 97,574     $ 104,609  
     
     
 
 
LIABILITIES AND STOCKHOLDERS’ EQUITY
 
Current liabilities:
               
 
Accounts payable
  $ 1,448     $ 1,288  
 
Accrued liabilities
    5,512       6,007  
 
Unearned revenue
    6,668       8,241  
     
     
 
   
Total current liabilities
    13,628       15,536  
Deferred revenue
          2,125  
     
     
 
   
Total liabilities
    13,628       17,661  
     
     
 
Commitments and contingencies
               
Stockholders’ equity:
               
 
Preferred stock, $.01 par value, 5,000,000 shares authorized; no shares issued and outstanding
           
 
Common stock, $.01 par value; 100,000,000 authorized and 30,518,858 and 30,176,159 shares issued and outstanding
    305       302  
 
Additional paid-in capital
    227,105       226,685  
 
Accumulated deficit
    (143,464 )     (140,039 )
     
     
 
   
Total stockholders’ equity
    83,946       86,948  
     
     
 
     
Total liabilities and stockholders’ equity
  $ 97,574     $ 104,609  
     
     
 

The accompanying notes are an integral part of these condensed consolidated financial statements

3


Table of Contents

QUOVADX, INC.

 
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except for per share amounts)
(Unaudited)
                                       
Three Months Ended Six Months Ended
June 30, June 30,


2003 2002 2003 2002




Revenue:
                               
 
License
  $ 7,242     $ 1,727     $ 12,582     $ 5,367  
 
Services
    4,317       6,434       8,871       13,462  
 
Recurring
    7,785       7,113       15,324       14,214  
     
     
     
     
 
   
Total revenue
    19,344       15,274       36,777       33,043  
     
     
     
     
 
Cost of revenue:
                               
 
License
    2,158       1,415       5,086       2,498  
 
Services
    3,129       4,682       6,132       8,519  
 
Recurring
    5,164       4,426       10,053       9,431  
     
     
     
     
 
   
Total cost of revenue
    10,451       10,523       21,271       20,448  
     
     
     
     
 
     
Gross profit
    8,893       4,751       15,506       12,595  
     
     
     
     
 
Operating expenses:
                               
 
Sales and marketing
    4,052       3,479       7,894       6,215  
 
General and administrative
    3,146       3,247       6,176       6,599  
 
Research and development
    2,246       1,777       4,493       3,209  
 
Amortization of acquired intangibles
    307       553       764       1,123  
     
     
     
     
 
   
Total operating expenses
    9,751       9,056       19,327       17,146  
     
     
     
     
 
Loss from operations
    (858 )     (4,305 )     (3,821 )     (4,551 )
 
Gain on sale of assets
                      87  
 
Interest income, net
    207       292       396       553  
     
     
     
     
 
Net loss
  $ (651 )   $ (4,013 )   $ (3,425 )   $ (3,911 )
     
     
     
     
 
Net loss per common share — basic and diluted
  $ (0.02 )   $ (0.13 )   $ (0.11 )   $ (0.13 )
     
     
     
     
 
Weighted average common shares outstanding — basic and diluted
    30,406       30,013       30,297       29,870  
     
     
     
     
 

The accompanying notes are an integral part of these condensed consolidated financial statements

4


Table of Contents

QUOVADX, INC.

 
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(Unaudited)
                       
Six Months Ended
June 30,

2003 2002


Cash flows from operating activities
               
Net loss
  $ (3,425 )   $ (3,911 )
Adjustments to reconcile net loss to net cash used in operating activities:
               
 
Depreciation and amortization
    4,446       4,273  
 
Amortization of acquired intangibles
    764       1,123  
 
Gain on sale of assets
          (87 )
 
Amortization of unearned compensation
          119  
 
Bad debt expense
    477        
 
Change in assets and liabilities:
               
   
Accounts receivable
    1,741       (2,718 )
   
Unbilled accounts receivable
    (2,466 )     1,063  
   
Other assets
    (1,220 )     (1,167 )
   
Accounts payable
    160       (820 )
   
Accrued liabilities
    (496 )     (3,982 )
   
Unearned and deferred revenue
    (3,698 )     243  
     
     
 
     
Net cash used in operating activities
    (3,717 )     (5,864 )
     
     
 
Cash flows from investing activities
               
 
Purchase of property and equipment
    (569 )     (774 )
 
Capitalized software
    (1,667 )     (2,075 )
 
Sales of short-term investments
    15,054       11,625  
 
Purchases of short-term investments
    (4,168 )     (4,000 )
 
Business acquisitions, net of acquired cash
          (1,633 )
     
     
 
     
Net cash provided by investing activities
    8,650       3,143  
     
     
 
Cash flows from financing activities
               
 
Proceeds from issuance of common stock
    423       857  
     
     
 
     
Net cash provided by financing activities
    423       857  
     
     
 
Net increase (decrease) in cash and cash equivalents
    5,356       (1,864 )
Cash and cash equivalents at beginning of period
    31,244       25,383  
     
     
 
Cash and cash equivalents at end of period
  $ 36,600     $ 23,519  
     
     
 
Supplemental disclosure of non-cash financing transactions
               
 
Issuance of common stock in business acquisition
  $     $ 920  
 
Receipt of stock in asset sale
          662  

The accompanying notes are an integral part of these condensed consolidated financial statements

5


Table of Contents

QUOVADX, INC.

 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
 
1. Interim Financial Statements

      The accompanying condensed consolidated financial statements of Quovadx, Inc. (“Quovadx,” the “Company,” “we” or “us”) have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted pursuant to such rules and regulations. However, we believe that the disclosures are adequate to make the information presented not misleading. The unaudited financial statements have been prepared on the same basis as our annual financial statements and reflect all adjustments, which include only normal recurring adjustments necessary for a fair presentation in accordance with accounting principles generally accepted in the United States. The results for the three and six months ended June 30, 2003 are not necessarily indicative of the results expected for the full year. These financial statements should be read in conjunction with the audited financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2002.

      Reclassifications. Certain prior year information has been reclassified to conform with the current year presentation.

 
2. Net Loss per Common Share

      Net loss per common share (“EPS”) is calculated in accordance with Statement of Financial Accounting Standards (“SFAS”) No. 128, “Earnings per Share.” Under the provisions of SFAS No. 128, basic EPS is computed by dividing the net income for the period by the weighted average number of common shares outstanding during the period. Diluted EPS reflects the potential dilution that could occur if stock options were exercised, resulting in the issuance of common stock that would share in the earnings of the Company. Potential dilution of the stock options exercisable into common stock is computed using the treasury stock method based on the average fair market value of the stock. In periods where the Company has a net loss the effect of common stock equivalents is excluded from the computation of diluted EPS since their effect would decrease the loss per share. The diluted weighted average common shares calculation for the three and six months ended June 30, 2003 and 2002 excludes 521,996 and 1,824,561 options, respectively, to purchase common stock because their effect would have been anti-dilutive.

      The following table sets forth the computation of the numerators and denominators in the basic and diluted net loss per common share calculations for the periods indicated (in thousands):

                                   
Three Months Ended Six Months Ended
June 30, June 30,


2003 2002 2003 2002




Numerator:
                               
 
Net loss available to common stockholders
  $ (651 )   $ (4,013 )   $ (3,425 )   $ (3,911 )
     
     
     
     
 
Denominator:
                               
 
Weighted average common shares outstanding — basic
    30,406       30,013       30,297       29,870  
 
Effect of dilutive securities:
                               
 
Employee stock options
                       
     
     
     
     
 
 
Weighed average common shares outstanding — diluted
    30,406       30,013       30,297       29,870  
     
     
     
     
 

6


Table of Contents

QUOVADX, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

 
3. Segment Information

      Segment information has been prepared in accordance with SFAS No. 131, “Disclosures about Segments of an Enterprise and Related Information.” The Company defines operating segments as components of an enterprise for which discrete financial information is available and is reviewed regularly by the chief operating decision-maker or decision-making group, to evaluate performance and make operating decisions. The chief operating decision-making group reviews the revenue and margin by the nature of the services provided and reviews the overall results of the Company. Accounting policies of the segments are the same as those described in the summary of significant accounting policies in the company’s annual report on form 10K for the year ended December 31, 2002.

      The Company operates in three segments: professional services, software licenses and recurring revenue. The professional services segment includes revenue generated from software implementation, development and integration. The software license segment includes revenue from perpetual software license sales and software subscriptions. The recurring revenue segment includes revenue generated from outsourcing, hosting, maintenance, transactions, and other recurring services.

      Following is a breakout by segment.

                                           
Software Professional Consolidated
License Services Recurring Other Total





(In thousands)
Three Months Ended June 30,
                                       
2003
                                       
 
Total revenue
  $ 7,242     $ 4,317     $ 7,785     $     $ 19,344  
 
Gross Profit
    5,084       1,188       2,621             8,893  
 
Assets
                      97,574 (1)     97,574  
 
Capital expenditures
                      273 (1)     273  
2002
                                       
 
Total revenue
  $ 1,727     $ 6,434     $ 7,113     $     $ 15,274  
 
Gross Profit
    312       1,752       2,687             4,751  
 
Assets
                      207,867 (1)     207,867  
 
Capital expenditures
                      505 (1)     505  
                                           
Software Professional Consolidated
License Services Recurring Other Total





(In thousands)
Six Months Ended June 30,
                                       
2003
                                       
 
Total revenue
  $ 12,582     $ 8,871     $ 15,324     $     $ 36,777  
 
Gross Profit
    7,496       2,739       5,271             15,506  
 
Assets
                      97,574 (1)     97,574  
 
Capital expenditures
                      569 (1)     569  
2002
                                       
 
Total revenue
  $ 5,367     $ 13,462     $ 14,214     $     $ 33,043  
 
Gross Profit
    2,869       4,943       4,783             12,595  
 
Assets
                      207,867 (1)     207,867  
 
Capital expenditures
                      774 (1)     774  


(1)  A breakout of assets and capital expenditures for all segments is not provided to our chief operating decision-maker. The other column represents the amount to reconcile to the consolidated total.

7


Table of Contents

QUOVADX, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

 
4. Goodwill and Other Intangibles

      The Company adopted SFAS No. 142, “Goodwill and Other Intangible Assets” in 2002. In accordance with SFAS No. 142, the Company did not record amortization expense related to goodwill for acquisitions entered into after July 1, 2001 and for all acquisitions as of January 1, 2002.

      SFAS No. 142, requires that the company test goodwill annually for impairment and more frequently if events or changes in circumstances indicate assets might be impaired. The Company performed a transitional impairment test upon the adoption of SFAS No. 142 on January 1, 2002 and recorded no impairment as a result of this test. The Company had identified the fourth quarter as the period for its annual impairment test. However, due to significant negative industry and economic trends affecting the market value of the Company’s common stock, the Company performed an interim test of goodwill impairment in the third quarter of 2002. As a result of this interim test, the Company recorded an impairment charge of $93.1 million to reduce goodwill based on the amount that the carrying value of the goodwill exceeded its fair value. This impairment charge eliminated goodwill associated with all previous acquisitions and related to each of the Company’s reportable segments.

      Intangible assets recognized in the Company’s acquisitions are being amortized over their estimated lives ranging from three to eight years. The following table provides information relating to the Company’s intangible assets as of June 30, 2003 (in thousands):

                   
Accumulated
Cost Amortization


Amortized intangible assets:
               
 
Customer base
  $ 5,965     $ (1,462 )
 
Tradenames, patents and other
    1,743       (744 )
     
     
 
 
Total
  $ 7,708     $ (2,206 )
     
     
 
 
5. Stock Option Compensation

      At June 30, 2003, the Company had three stock option plans and an employee stock purchase plan. The Company has elected to account for stock-based compensation arrangements using the intrinsic value method under the provisions of Accounting Principles Board Opinion No. 25 (“APB 25”), “Accounting for Stock Issued to Employees”. Under this method, stock compensation is recognized to the extent that the exercise price is less than the market price for the underlying stock on the date of grant. The following table illustrates the effect on net loss and net loss per share if the Company had applied the fair value recognition provisions of SFAS No. 123, “Accounting for Stock-Based Compensation,” to stock-based employee compensation (in thousands except per share amounts).

                                   
Three Months Ended Six Months Ended
June 30, June 30,


2003 2002 2003 2002




Net loss:
                               
 
As reported
  $ (651 )   $ (4,013 )   $ (3,425 )   $ (3,911 )
 
Plus: stock based compensation recognized under intrinsic value method
          53             119  
 
Less: stock based compensation under fair value method
    (2,451 )     (2,787 )     (3,455 )     (4,190 )
     
     
     
     
 
 
Pro forma net loss
  $ (3,102 )   $ (6,747 )   $ (6,880 )   $ (7,982 )
     
     
     
     
 
Net loss per common share:
                               
 
As reported
  $ (0.02 )   $ (0.13 )   $ (0.11 )   $ (0.13 )
 
Pro forma
    (0.10 )     (0.22 )     (0.23 )     (0.27 )

8


Table of Contents

Item 2.     Management’s Discussion and Analysis of Financial Condition and Results of Operations

      The following discussion should be read in conjunction with the condensed financial statements and the related notes that appear elsewhere in this document.

FORWARD-LOOKING STATEMENTS

      All statements, trend analysis and other information contained in this Form 10-Q of Quovadx, Inc. (“Quovadx”, the “Company”, “we” or “us”) and the information incorporated by reference which are not historical in nature are forward-looking statements within the meaning of the Private-Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, discussion relative to markets for our products and trends in revenue, gross margins and anticipated expense levels, as well as other statements including words such as “anticipate,” “believe,” “plan,” “estimate,” “expect” and “intend” and other similar expressions. All statements regarding the Company’s expected financial position and operating results, business strategy, financing plans, forecast trends relating to our industry are forward-looking statements. These forward-looking statements are subject to business and economic risks and uncertainties, and our actual results of operations may differ materially from those contained in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in “Risk Factors” below.

Critical Accounting Policies

      The consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States which require management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. The Company relied on significant estimates in preparing the financial statements to evaluate the adequacy of the allowance for bad debt, the percentage of completion of fixed priced professional service contracts, the recoverability of deferred tax assets and the recoverability of capitalized software costs. Actual results could differ from those estimates. The Company believes that of its significant accounting policies, the following involve a higher degree of judgment and complexity.

 
      Revenue

      The Company recognizes revenue in accordance with the provisions of Statement of Position (“SOP”) 97-2, “Software Revenue Recognition,” as amended, and SOP 81-1, “Accounting for Performance of Construction-Type and Certain Production-Type Contracts.”

      License agreements generally provide that customers pay a license fee based on a specified number of instances of the software and the type of software modules licensed. Customers that purchase licenses generally enter into renewable one-year maintenance agreements that entitle the customer to receive unspecified updates on the software licensed, error corrections and telephone support, generally for a fixed fee.

      The methodology the Company uses to recognize software license and related services revenue is dependent on whether the Company has established vendor-specific objective evidence (“VSOE”) of fair value for the separate elements of a multiple-element agreement. If an agreement includes both license and service elements, the license fee is recognized on delivery of the software if the remaining services are not essential to the functionality of the software, the collection of the fees is probable, the fees are fixed and determinable, an agreement is signed and the Company has established VSOE of fair value for the remaining elements. Revenue from the related services is recognized as the services are provided. When the related services are essential to the functionality of the base product or when the Company has not established VSOE of fair value for the remaining services, the software license fees are deferred and the entire contract is recognized as the services are provided.

      Professional services revenue represents software development, implementation and consulting services. When derived from a fixed price contract, and collection of fees is probable, the Company recognizes professional services revenue using the percentage-of-completion method of accounting. When derived from a

9


Table of Contents

time-and-materials contract, and the collection of fees is probable, the Company recognizes professional services revenue as the services are provided.

      When revenue is recognized using the percentage-of-completion basis of accounting, the Company’s management estimates the costs to complete the services to be provided under the contract. The Company may encounter budget and schedule overruns caused by increased material, labor or overhead costs. Adjustments to cost estimates are made in the period in which the facts requiring such revisions become known. Estimated losses, if any, are recorded in the period in which the current estimates of the costs to complete the services exceed the revenue to be recognized under the contract.

      Maintenance revenue is derived from agreements for providing unspecified software updates, error corrections and telephone support. Maintenance revenue is recognized ratably over the maintenance period, which is generally 12 months.

      Process management and services revenue represent application hosting, transaction processing and other services. When the fees are fixed and determinable, and collection of the fees is probable, revenue is recognized over the service period. When the fees are charged on a per-transaction basis and collection of the fees is probable, revenue is recognized as the transactions are processed.

      When collection of fees is not probable, revenue is recognized as cash is collected. The Company does not require collateral from its customers.

 
      Allowance for Doubtful Accounts

      The Company maintains allowances for doubtful accounts for estimated losses resulting from the inability of certain customers to pay their accounts receivable balances. The Company assesses financial condition of its customers to determine if there is an impairment of their ability to make payments and additional allowances may be required if the financial condition of the Company’s customers deteriorates.

 
      Software Development Costs

      Software development costs are required to be expensed until the point that technological feasibility of the product is established. Once technological feasibility is established, such costs are capitalized until the product has reached general availability. The establishment of technological feasibility and continuing evaluation of the recoverability of the capitalized software development costs requires management’s judgment with respect to the impact of external factors such as future revenue, estimated economic life and changes in software and hardware technologies. Capitalized software development costs are amortized on a straight-line basis over an estimated life, which is generally three years. The Company capitalizes internal and external labor costs incurred in developing the software once technological feasibility is attained. At June 30, 2003, the Company had $5.3 million of capitalized software development costs, net of amortization.

10


Table of Contents

 
      Results of Operations

      The following table sets forth, for the periods indicated, certain items from the Company’s statements of operations as a percentage of total revenue:

                                     
Three Months Ended Six Months Ended
June 30, June 30,


2003 2002 2003 2002




Revenue:
                               
 
License
    37.4 %     11.3 %     34.2 %     16.3 %
 
Service
    22.3       42.1       24.1       40.7  
 
Recurring
    40.3       46.6       41.7       43.0  
     
     
     
     
 
   
Total revenue
    100.0       100.0       100.0       100.0  
     
     
     
     
 
Cost of revenue:
                               
 
License
    11.1       9.3       13.8       7.6  
 
Service
    16.2       30.6       16.7       25.8  
 
Recurring
    26.7       29.0       27.3       28.5  
     
     
     
     
 
   
Total cost of revenue
    54.0       68.9       57.8       61.9  
     
     
     
     
 
 
Gross profit
    46.0       31.1       42.2       38.1  
     
     
     
     
 
Operating Expenses:
                               
 
Sales and marketing
    20.9       22.8       21.5       18.8  
 
General and administrative
    16.3       21.3       16.8       20.0  
 
Research and development
    11.6       11.6       12.2       9.7  
 
Amortization of acquired intangibles
    1.6       3.6       2.1       3.4  
     
     
     
     
 
   
Total operating expenses
    50.4       59.3       52.6       51.9  
     
     
     
     
 
Loss from operations
    (4.4 )     (28.2 )     (10.4 )     (13.8 )
 
Gain on sale of assets
                      0.3  
 
Interest income, net
    1.1       1.9       1.1       1.7  
     
     
     
     
 
Net income (loss)
    (3.3 )%     (26.3 )%     (9.3 )%     (11.8 )%
     
     
     
     
 

Comparison of the Company’s Results for the Three Months Ended June 30, 2003 and 2002.

      Total revenue. Total revenue increased $4.1 million, or 27%, to $19.3 million for the three months ended June 30, 2003 from $15.3 million for the three months ended June 30, 2002. Software license revenue was $7.2 million for the three months ended June 30, 2003, an increase of $5.5 million or 319% from the three months ended June 30, 2002. The increase in software license revenue was primarily due to the acceleration of $2.9 million of deferred software revenue from the early termination of a 4-year customer agreement and increased software sales. Recurring revenue increased 9% to $7.8 million for the three months ended June 30, 2003 from $7.1 million in the comparable 2002 period primarily due to an increase in revenue generated from the claims transaction business. Professional services revenue decreased $2.1 million from the second quarter of 2002 due to the completion of several large contracts in the third quarter of 2002.

      Cost of revenue. Cost of revenue decreased $0.1 million, or 1%, to $10.4 million for the three months ended June 30, 2003 from $10.5 million from the three months ended June 30, 2002. Cost of revenue for the license segment increased due to increased software royalty expense of $0.4 million from higher sales of third party software in the three months ended June 30, 2003. In addition, software amortization increased $0.2 million over the three months ended June 30, 2002 primarily due an increase in the Company’s capitalized software balance from the continued development of the Company’s software products. Recurring revenue costs increased

11


Table of Contents

17% to $5.2 million for the second quarter of 2003 from the comparable period in 2002 due to an increase in the Company’s claims transaction business and increased royalty expense on sales of maintenance contracts for third party software. Professional services cost of revenue decreased due to a decline in headcount from the three months ended June 30, 2002. As a percentage of revenue, cost of revenue decreased from 68.9% for the three months ended June 30, 2002 to 54.0% for the three months ended June 30, 2003.

      Sales and marketing. Sales and marketing expenses increased $0.6 million, or 16%, to $4.1 million for the three months ended June 30, 2003 from $3.5 million for the three months ended June 30, 2002. Sales and marketing expenses increased due to an increase in the size of the Company’s sales force and product marketing professionals. Commission expense was also higher due to increased software sales. As a percentage of revenue, sales and marketing expense decreased 1.9% to 20.9% for the three months ended June 30, 2003 compared to 22.8% for the three months ended June 30, 2002.

      General and administrative. General and administrative expenses decreased $0.1 million, or 3%, to $3.1 million for the three months ended June 30, 2003 from $3.2 million from the year earlier period. The decrease in general and administrative expenses was primarily due to lower spending on legal and telecommunications expense. As a percentage of revenue, general and administrative expense decreased 5.0% to 16.3% for the three months ended June 30, 2003 compared to 21.3% for the three months ended June 30, 2002.

      Research and development. Research and development expenses increased $0.4 million from, or 26%, to $2.2 million for the three months ended June 30, 2003 from $1.8 million for the three months ended June 30, 2002. This increase is primarily due to an increase in salaries, benefits, and contractor expense of $0.4 million from the year earlier period. As a percentage of revenue, research and development expense remained was 11.6% for both the three month periods ended June 30, 2003 and 2002.

      Amortization of acquired intangibles. The amortization of acquired intangibles results from assets purchased through our business acquisitions. Intangible assets amortization for the three months ended June 30, 2003 and 2002 was $0.3 million and $0.5 million, respectively. The decrease is due to the full amortization of an intangible asset acquired in the Healthcare.com purchase.

      Interest income. Interest income includes interest income on cash, cash equivalents and short-term investment balances. Interest income decreased $0.1 million, to $0.2 million for the three months ended June 30, 2003 from $0.3 million for the prior year period. The decrease in interest income is due to lower interest rates and the decrease in the Company’s cash and short-term investments balance used to fund operations.

      Income tax benefit. A provision for federal and state income taxes has not been recorded for the three months ended June 30, 2003 and 2002, as we have incurred a net operating loss for the 2003 period and for the 2002 full year. We believe that, based on the history of losses and other factors, the weight of available evidence indicates that it is more likely than not that we will not be able to realize our deferred tax assets, and thus a full valuation allowance has been recorded against such assets as of June 30, 2003 and December 31, 2002.

      Segment margins. Segment gross margins are as follows:

                         
Three Months Ended
June 30,

Increase/
2003 2002 (Decrease)



Software license
  $ 5,084     $ 312     $ 4,772  
Professional services
    1,188       1,752       (564 )
Recurring revenue
    2,621       2,687       (66 )
     
     
     
 
    $ 8,893     $ 4,751     $ 4,142  
     
     
     
 

      The increase in software license margin is primarily due to the acceleration of $2.9 million of deferred software revenue from the early termination of a 4-year customer agreement. Margin for professional services decreased primarily due to the completion of several large contracts in the third quarter of 2002.

12


Table of Contents

Comparison of the Company’s Results for the Six Months Ended June 30, 2003 and 2002.

      Total revenue. Total revenue increased $3.8 million, or 11%, to $36.8 million for the six months ended June 30, 2003 from $33.0 million for the six months ended June 30, 2002. Software license revenue increased $7.2 million over the first half of 2002, which was primarily due to the acceleration of $2.9 million of deferred software revenue from the early termination of a 4-year customer agreement and increased software sales. Recurring revenue increased 8% to $15.3 million for the six months ended June 30, 2003 from $14.2 million in the comparable 2002 period primarily due to an increase in revenue generated from the claims transaction and outsourcing businesses. Professional services revenue declined $4.6 million or 34% from the six months ended June 30, 2002 to $8.9 million for the six months ended June 30, 2003 due to the completion of several large contracts in the third quarter of 2002.

      Cost of revenue. Cost of revenue, which includes amortization of software, increased $0.9 million, or 4%, to $21.3 million for the six months ended June 30, 2003 from $20.4 million for the six months ended June 30, 2002. Cost of revenue for the license segment increased due to an increase in software royalty expense of $1.7 million as a result of increased sales of third party software in the six months ended June 30, 2003. In addition, software amortization increased $0.7 million over the six months ended June 30, 2002 primarily due an increase in the Company’s capitalized software balance from the continued development of the Company’s software. Recurring revenue costs increased 7% to $10.1 million for the six months ended June 30, 2003 from the comparable period in 2002 due to an increase in the Company’s claims transaction business and increased royalty expense on sales of maintenance contracts for third party software. Professional services cost of revenue decreased due to a decline in headcount from the six months ended June 30, 2002. As a percentage of revenue, cost of revenue decreased from 61.9% for the six months ended June 30, 2002 to 57.8% for the six months ended June 30, 2003.

      Sales and marketing. Sales and marketing expenses increased $1.7 million, or 27%, to $7.9 million for the six months ended June 30, 2003 from $6.2 million for the six months ended June 30, 2002. Sales and marketing expenses increased due to an increase in the size of the Company’s sales force and product marketing professionals. Bonus and commission expense was also higher due to an increase in software sales. As a percentage of revenue, sales and marketing expense increased 2.7% to 21.5% for the six months ended June 30, 2003 compared to 18.8% for the six months ended June 30, 2002.

      General and administrative. General and administrative expenses decreased $0.4 million, or 6%, to $6.2 million for the six months ended June 30, 2003 from $6.6 million from the year earlier period. The decrease in general and administrative expenses was primarily due to lower spending on legal and telecommunications expense. As a percentage of revenue, general and administrative expense decreased 3.2% to 16.8% for the six months ended June 30, 2003 compared to 20.0% for the six months ended June 30, 2002.

      Research and development. Research and development expenses increased $1.3 million, or 40%, to $4.5 million for the six months ended June 30, 2003 from $3.2 million for the six months ended June 30, 2002. This increase is due to a decline in the size and number of capitalizable software development projects and an increase in salaries, benefits, and contractors expense. Capitalized software development costs decreased from $2.1 million in the first half of 2002 to $1.7 million in the first half of 2003. As a percentage of revenue, research and development expense increased 2.5% to 12.2% for the six months ended June 30, 2003 compared to 9.7% for the six months ended June 30, 2002.

      Amortization of acquired intangibles. The amortization of acquired intangibles results from assets purchased through our business acquisitions. Intangible assets amortization for the six months ended June 30, 2003 and 2002 was $0.8 million and $1.1 million, respectively. The decrease is due to the full amortization of an intangible asset acquired in the Healthcare.com purchase in the first quarter of 2003.

      Interest income. Interest income includes interest income on cash, cash equivalents and short-term investment balances. Interest income decreased $0.2 million, to $0.4 million for the six months ended June 30, 2003 from $0.6 million for the prior year period. The decrease in interest income is due to lower interest rates and the decrease in the Company’s cash and short-term investments balance used to fund operations.

13


Table of Contents

      Income tax benefit. A provision for federal and state income taxes has not been recorded for the six months ended June 30, 2003 and 2002, as we have incurred a net operating loss for the 2003 period and for the 2002 full year. We believe that, based on the history of losses and other factors, the weight of available evidence indicates that it is more likely than not that we will not be able to realize our deferred tax assets, and thus a full valuation allowance has been recorded against such assets as of June 30, 2003 and December 31, 2002.

      Segment margins. Segment margins are as follows:

                         
Six Months Ended
June 30,

Increase/
2003 2002 (Decrease)



Software license
  $ 7,496     $ 2,869     $ 4,627  
Professional services
    2,739       4,943       (2,204 )
Recurring revenue
    5,271       4,783       488  
     
     
     
 
    $ 15,506     $ 12,595     $ 2,911  
     
     
     
 

      The increase in software license margin is primarily due to the acceleration of $2.9 million of deferred software revenue from the early termination of a 4-year customer agreement and increased software sales. Margin for professional services decreased from the six months ended June 30, 2002 primarily due to the completion of several large contracts in the third quarter of 2002.

Liquidity and Capital Resources

      We have historically financed our operations through a combination of cash flow from operations, private sales of common and convertible preferred stock, issuances of convertible promissory notes and public sales of common stock. Since our IPO in February 2000, we have financed our operations with the proceeds of that offering and cash flow from operations.

      We expect to use our cash, cash equivalents and short-term investments for general corporate purposes, working capital and capital expenditures, to fund our operations and to continue expanding our product offerings. The amounts and timing of our actual expenditures will depend upon numerous factors, including the status of our product development efforts, marketing and sales activities, the amount of cash generated by our operations and competition. We may find it necessary or advisable to use portions of our cash, cash equivalents and short-term investments for other purposes. A portion of our cash, cash equivalents and short-term investments may also be used to acquire or invest in complementary businesses or products or to obtain the right to use synergistic technologies. Pending use of our cash, cash equivalents and short-term investments for the above purposes, we intend to invest such funds in short-term, interest-bearing, investment-grade securities.

      Net cash used in operating activities for the six months ended June 30, 2003 was $3.7 million compared to $5.9 million for the six months ended June 30, 2002. The decrease in net cash used in operating activities for the six months ended June 30, 2003 is primarily attributable to the payment of acquisition related accounts payable and accrued liabilities during the first half of 2002.

      Net cash provided by investing activities for the six months ended June 30, 2003 was $8.6 million compared to $3.1 million in the same period of the prior year. Investing activities consist of purchases of computer hardware and software, office furniture and equipment, purchase and sales of investments, additions to capitalized software, and cash used in the business acquisitions. There was an increase of $3.3 million in net sales of short-term investments from the six months ended June 30, 2002. In addition, the $1.6 million was used to fund an acquisition in the 2002 period.

      Net cash provided by financing activities for the six months ended June 30, 2003 decreased $0.4 million, which was primarily related to the exercise of stock options.

      The Company has commitments pursuant to certain real property lease obligations, and these obligations have not materially changed since December 31, 2002.

14


Table of Contents

      We expect our current cash resources will be sufficient to meet our requirements for the next 18 months. We may need to raise additional capital to support expansion, to develop new or enhanced applications, services and product offerings, to respond to competitive pressures, to acquire complementary businesses or technologies or to take advantage of unanticipated opportunities. If we need additional capital, we would try to raise the additional funds by selling debt or equity securities, by entering into strategic relationships or through other arrangements. We cannot assure you that we would be able to raise any additional amounts on reasonable terms, or at all, if they are needed.

RISK FACTORS

      The following risk factors could materially and adversely affect our operating results and could cause actual events to differ materially from those predicted in any forward-looking statements related to our business.

We have historically incurred losses and we may not be able to sustain profitability.

      Although we have had profitable quarters, we incurred losses for the six months ended June 30, 2003 and the years ended December 31, 2002, 2001 and 2000. As of June 30, 2003, we had an accumulated deficit of $143 million. Since our IPO in February of 2000, we have funded our business primarily from the cash generated from the sale of our stock and cash flow from operations. We expect to continue to incur significant sales and marketing, research and development and general and administrative expenses that may exceed our gross margin. As a result, we may experience losses and negative cash flows in the future. Failure to achieve and maintain profitability may cause our stock price to decline and impair our business and financial prospects.

Our quarterly operating results are likely to fluctuate significantly and may fail to meet the expectations of securities analysts and investors, causing our share price to decline.

      Our quarterly operating results have fluctuated significantly in the past and are likely to fluctuate in the future. Moreover, our operating results in some quarters may not meet the expectations of stock market analysts and investors. In that event, our stock price would likely decline. Further declines in our stock price may impair our business prospects and our financial condition. As a result of our limited history of profitable operations, our business strategy, and the evolving nature of the markets in which we compete, we may have difficulty accurately forecasting our revenue in any given period. In addition to the factors discussed elsewhere in this section, a number of factors may cause our revenue to fall short of our expectations or cause fluctuations in our operating results, including:

  •  delay in our introduction of new applications, services and products offerings and enhancements of our existing solutions;
 
  •  the capital and expense budgeting decisions of our existing and prospective customers;
 
  •  the loss of a major customer;
 
  •  the amount and timing of operating costs and capital expenditures relating to the implementation of our business strategy;
 
  •  increased product development and engineering expenditures required to keep pace with technological changes;
 
  •  the announcement or introduction of new or enhanced products or services by our competitors.

We have embarked on a strategy to significantly increase software sales as our principal source of revenue. If that strategy is not successful, our business may be harmed.

      We have invested and continue to invest significant financial and management resources in reorganizing and enhancing our software sales effort. In recent months, we have hired what we believe are top caliber sales talent, and we have reformulated our sales materials and our presentation strategy and we have reorganized our sales and marketing functions, all with a goal of generating an increased percentage of our revenue from sales of our

15


Table of Contents

software products. These efforts have been expensive and they have required, and we expect will continue to require, considerable executive management time and oversight, thus diverting resources from other aspects of our business. If for any reason this strategy is not successful, and we do not achieve increased software sales as anticipated, then our stock price will decline, and our business prospects and financial condition will be adversely affected.

The market for business process management and integration software may not grow as quickly as we anticipate, which would cause our revenue to fall below expectations.

      The market for business process management and integration software is relatively new and evolving. We earn a substantial portion of our revenue from sales of our business process management software, including application integration software, and related services. We expect to earn substantially all of our revenue in the future from sales of these products and services. Our future financial performance will depend on continued growth in the number of organizations demanding software and services for business process management and integration, requiring information delivery, and seeking outside vendors to develop, manage and maintain this software for their critical applications. Many of our potential customers have made significant investments in internally developed systems and would incur significant costs in switching to our products, which may substantially inhibit the growth of our software market. If the market fails to grow, or grows more slowly than we expect, our sales will be adversely affected. In addition, a weakening global economy may lead to longer sales cycle and slower sales growth.

Our acquisition strategy could cause financial or operational problems.

      Our success depends on our ability to continually enhance and broaden our product offerings in response to changing technology, customer demands, and competitive pressures. To this end, we may acquire new and complementary businesses, products or technologies. We do not know if we will be able to complete any acquisitions or that we will be able to successfully integrate any acquired businesses, operate them profitably, or retain their key employees. Integrating any newly acquired business, product or technology could be expensive and time-consuming, could disrupt our ongoing business, and could distract our management. We may face competition for acquisition targets from larger and more established companies with greater financial resources. In addition, in order to finance any acquisitions, we might need to raise additional funds through public or private financings. In that event, we could be forced to obtain equity or debt financing on terms that are not favorable to us and, in the case of equity financing, that results in dilution to our stockholders. If we are unable to integrate any newly acquired entity, products or technology effectively, our business, financial condition and operating results would suffer. In addition, the amortization of intangible assets or other charges resulting from the cost of acquisitions could harm our operating results.

If we cannot execute our strategy to establish and maintain our relationships with established healthcare industry participants, our applications, services and products may not achieve healthcare market acceptance.

      The healthcare industry is our most important market. Relationships with established healthcare industry participants are critical to our success. These relationships include customer, vendor, distributor and co-marketer relationships. To date, we have established a number of these relationships. Once we have set up a relationship with an established healthcare industry participant, we rely on that participant’s ability to assist us in generating increased acceptance and use of our applications, services and product offerings. We have limited experience in maintaining relationships with healthcare industry participants. Additionally, the other parties to these relationships may not view these relationships with us as significant to their own business, and they may reassess their commitment to us or decide to compete directly with us in the future. We generally do not have agreements that prohibit them from competing against us directly or from contracting with our competitors. We cannot guarantee that any such party will perform its obligations as agreed or contemplated or that we would be able to specifically enforce any agreement with it. Our arrangements generally do not establish minimum performance requirements, but instead rely on the voluntary efforts of the other party. Therefore, we cannot guarantee that these relationships will be successful. If we were to lose any of these relationships, or if the other parties were to fail to collaborate

16


Table of Contents

with us to pursue additional business relationships, we would not be able to execute our business plans and our business would suffer significantly. Moreover, we may not experience increased use of our applications, services and product offerings even if we establish and maintain these relationships.

If our transaction hosting services suffer interruptions, our business and reputation could be harmed.

      In the past, our customers have experienced some interruptions with our transaction hosting services. Similar interruptions may continue to occur from time to time. These interruptions could be due to hardware and operating system failures. We currently process customer transactions and data at our facility in Albuquerque, New Mexico as well as in a third-party hosting facility in Santa Clara, California. Although we have safeguards for emergencies in each location, we do not have fully operational procedures for information processing facilities if either primary facility is not functioning. The occurrence of a major catastrophic event or other system failure at either facility could interrupt data processing or result in the loss of stored data. In addition, we depend on the efficient operation of Internet connections from customers to our systems. These connections, in turn, depend on the efficient operation of web browsers, Internet service providers and Internet backbone service providers, all of which have had periodic operational problems or experienced outages. Any system delays, failures or loss of data, whatever the cause, could reduce customer satisfaction with our applications, services and product offerings.

      We expect a significant portion of our revenue to be derived from customers who use our transaction hosting services. As a result, our business will suffer if we experience frequent or long system interruptions that result in the unavailability or reduced performance of our hosting capability. We expect to experience occasional temporary capacity constraints due to sharply increased traffic, which may cause unanticipated system disruptions, slower response times, impaired quality and degradation in levels of customer service. If this were to happen on more than an occasional and temporary basis, our business and reputation could be seriously harmed.

If security of our customer and patient information is compromised, patient care could suffer, we could be liable for damages and our reputation could decline.

      We retain confidential customer and patient information in our processing centers. Therefore, it is critical that our facilities and infrastructure remain secure and that our facilities and infrastructure are perceived by the marketplace to be secure. Despite the implementation of security measures, our infrastructure may be vulnerable to physical break-ins, computer viruses, programming errors, attacks by third parties or similar disruptive problems. If we fail to meet our clients’ expectations, we could be liable for damages and our reputation could suffer. In addition, patient care could suffer and we could be liable if our systems fail to deliver correct information in a timely manner. Our insurance may not protect us from this risk.

If we fail to meet performance standards we may experience a decline in revenue.

      Many of our transaction and hosting service agreements contain performance standards. If we fail to meet these standards, our customers could terminate their agreements with us. The loss of any of those service agreements would cause a decline in our revenue. Additionally, we may be unable to expand or adapt our transaction and hosting network infrastructure to meet new demands on a timely basis and at a commercially reasonable cost, or at all.

If compliance with government regulation of healthcare becomes costly and difficult for our customers, we may not be able to grow our business.

      Participants in the healthcare industry are subject to extensive and frequently changing regulation under numerous laws administered by governmental entities at the federal, state and local levels, some of which are, and others of which may be, applicable to our business. Furthermore, our healthcare service provider, payer and plan customers are also subject to a wide variety of laws and regulations that could affect the nature and scope of their relationships with us.

      The healthcare market itself is highly regulated and subject to changing political, economic and regulatory influences. These factors affect the purchasing practices and operations of healthcare organizations. Changes in

17


Table of Contents

current healthcare financing and reimbursement systems, such as modifications which may be required by the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”), may cause us to make unplanned enhancements of software applications or services, result in delays or cancellations of orders, or result in the revocation of endorsement of our applications and services by healthcare participants. The effect of HIPAA is difficult to predict and there can be no assurances that we will adequately address the business risks created by HIPAA and its implementation or that we will be able to take advantage of any resulting business opportunities.

      Federal and state legislatures have periodically considered programs to reform or amend the U.S. healthcare system at both the federal and state level. These programs may contain proposals to increase governmental involvement in healthcare, lower reimbursement rates or otherwise change the environment in which healthcare market participants operate. Healthcare market participants may respond by reducing their investments or postponing investment decisions, including investments in our applications and services. We do not know what effect any proposals would have on our business.

Because we provide utilization review services, we may be liable for the denial of payments for medical claims or medical services.

      One of the functions of our applications is automatic adjudication of whether a claim for payment or service should be denied or whether existing coverage should be continued based upon particular plans, contracts and industry-standard, clinical-support criteria. Our payer customers are ultimately responsible for deciding whether to deny claims for payment or medical services. It is possible, however, that our customers may assert that we are liable for denying payment of covered medical claims or medical service. The contractual protections included in our customer contracts and our insurance coverage may not be sufficient to protect us against such liability.

As we continue to build our international sales, we are subject to increased regulation and uncertainties in the international marketplace.

      Among other things, our core products contain strong encryption technology that is subject to export control regulation. These regulations prohibit us from selling in certain countries and to certain persons. Our inadvertent failure to properly restrict our sales could subject us and our management to fines and other sanctions and impair our financial condition and our reputation. Additionally, in the international marketplace we face increased uncertainty of enforcement of contractual provisions and enforcement of judgments in our dealings with non-U.S. persons. Our inability to properly defend or enforce our contract rights could materially impair our business prospects and financial condition.

We may face product-related liabilities that could force us to pay damages, which would hurt our reputation and financial condition.

      Although both we and our customers test our applications, services and product offerings, they may contain defects or result in system failures. These defects or problems could result in the loss of or delay in generating revenue, loss of market share, failure to achieve market acceptance, diversion of development resources, injury to our reputation or increased insurance costs. In particular, we market software products that are designed to assist our healthcare customers in meeting their HIPAA compliance obligations. Failure of these products to perform as intended could cause our customers to incur significant fines and penalties for non-compliance, which in turn could result in damages and claims against us. Our contracts generally limit our liability arising from our errors; however, these provisions may not be enforceable and may not protect us from liability. While we have general liability insurance that we believe is adequate, including coverage for errors and omissions, we may not be able to maintain this insurance on reasonable terms in the future. In addition, our insurance may not be sufficient to cover large claims and our insurer could disclaim coverage on claims. If we are liable for an uninsured or underinsured claim or if our premiums increase significantly, our financial condition could be materially harmed.

If we do not establish and maintain our brand, our reputation could be adversely affected.

      In order to increase our customer base and expand our online traffic, we must establish, maintain and strengthen our brand. For us to be successful in establishing our brand, professionals in the healthcare and other

18


Table of Contents

targeted markets must perceive us as offering quality, cost-effective, communications, information and administrative services. Our reputation and brand name could be harmed if we experience difficulties in introducing new applications, services and product offerings, if these applications, services and product offerings are not accepted by customers, if we are required to discontinue existing applications, services and product offerings or if our products and services do not function properly.

We are subjected to many risks because our business is dependent on our intellectual proprietary rights.

      We are exposed to infringement risks. Our intellectual property is important to our business. We may be subject to intellectual property infringement claims as the number of our competitors grows and the functionality of our applications overlaps with competitive offerings. These claims, whether or not meritorious, could be expensive, divert our attention from operating our company, result in costly litigation, cause product shipment delays, or require us to enter into royalty or licensing agreements, any of which could seriously harm our business, financial condition and results of operations. If we become liable to third parties for infringing on their intellectual property rights, we would be required to pay a substantial damage award and to develop non-infringing technology, obtain a license or cease selling the applications that contain the infringing intellectual property. We may be unable to develop non-infringing technology or obtain a license on commercially reasonable terms, or at all. In the event an intellectual property claim against us was successful and we could not obtain a license on acceptable terms, license a substitute technology or redesign to avoid infringement, most of our contracts would require us to refund a portion of the software license fees; our business, financial condition and results of operations would be seriously harmed. In addition, we may not be able to protect against misappropriation of our intellectual property. Third parties may infringe upon our intellectual property rights, we may not detect this unauthorized use and we may be unable to enforce our rights.

      We rely on third parties for technology in our products. We depend upon third-party suppliers and licensors to provide software that is incorporated in certain of our products and the products that we distribute. We have no control over the scheduling and quality of work of these third-party software suppliers and licensors. Additionally, the third-party software may not continue to be available to us on commercially reasonable terms, or at all. Our agreements to license certain third-party software will terminate after specified dates unless they are renewed. We expect to sell multiple products to the same customers and problems with the third party technology in one product may adversely affect sales of other products to the same customer.

      Our products may be affected by unknown software defects. Our products depend on complex software, both internally developed and licensed from third parties. Complex software often contains defects, particularly when first introduced or when enhancements or new versions are released. Although we conduct extensive testing, we may not discover software defects that affect our new or current products or enhancements until after they are deployed. To date, we have not experienced any material software defects, however despite continued testing, defects may occur in our software. These defects could cause performance interruptions, which could damage our reputation with existing or potential customers, increase our service costs, cause us to lose revenue, delay market acceptance or divert our development resources, any of which could cause our business to suffer.

 
Item 3.      Quantitative and Qualitative Disclosures About Market Risk

      We currently develop and market our products primarily in the United States. As a majority of sales are currently made in U.S. dollars, a strengthening of the dollar could make our product less competitive in foreign markets. Our interest income is sensitive to changes in the general level of U.S. interest rates. Due to the short term-term nature of our investments, we believe that there is no material interest risk exposure. Based on the foregoing, no quantitative disclosures have been provided.

 
Item 4.      Controls and Procedures

(a) Evaluation of disclosure controls and procedures.

Our chief executive officer and our chief financial officer, after evaluating our “disclosure controls and procedures” (as defined in Securities Exchange Act of 1934 (the “Exchange Act”) Rules 13a-15(e) and

19


Table of Contents

15-d-15(e)) as of the end of the period covered by this Quarterly Report on Form 10-Q (“Evaluation Date”) have concluded that as of the Evaluation Date, our disclosure controls and procedures are effective to ensure that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms.

(b) Changes in internal control over financial reporting.

There was no change in our internal control over financial reporting that occurred during the period covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially effect, our internal control over financial reporting.

PART II OTHER INFORMATION

 
Item 1.      Legal Proceedings

      On November 14, 2001, a shareholder class action complaint was filed in the United States District Court, Southern District of New York. On April 19, 2002, plaintiffs filed an amended complaint. The amended complaint asserts that the prospectus from the Company’s February 10, 2000 initial public offering (“IPO”) failed to disclose certain alleged improper actions by various underwriters for the offering in the allocation of the IPO shares. The amended complaint alleges claims against certain underwriters, the Company and certain officers and directors under the Securities Act of 1933 and the Securities Exchange Act of 1934 ( Bartula v. XCare.net, Inc., et al., Case No. 01-CV-10075). Similar complaints have been filed concerning more than 300 other IPO’s; all of these cases have been coordinated as In re Initial Public Offering Securities Litigation, 21 MC 92. In a negotiated agreement, individual defendants, including all of the individuals named in the complaint filed against the Company, were dismissed without prejudice, subject to a tolling agreement. Issuer and underwriter defendants in these cases filed motions to dismiss and, on February 19, 2003, the Court issued an opinion and order on those motions that dismissed selected claims against certain defendants, including the Rule 10b-5 fraud claims against the Company, leaving only the Section 11 strict liability claims under the Securities Act of 1933 against the Company. A committee of our Board of Directors has approved a settlement proposal made by the plaintiffs, but the settlement is subject to a number of conditions. If the settlement is not achieved, the Company will continue to aggressively defend the claims. The Company believes it has meritorious defenses. We do not believe that the outcome of this action will have a material adverse effect on our financial position, results of operations or liquidity; however, litigation is inherently uncertain and we can make no assurance as to the ultimate outcome or effect.

      The Company, and its wholly owned subsidiary Healthcare.com Corporation, are currently litigating a dispute with Hawaii Employees Retirement System (HERS) regarding a contract entered into in October 1999 between HERS and Thermo Information Solutions, subsequently assigned to Healthcare.com. On June 19, 2002, after exhausting its administrative remedies under Hawaii state law, Healthcare.com filed a complaint against HERS in the Circuit Court of the First Circuit, State of Hawaii. The complaint asserts that HERS is in breach of its obligations under the contract, and demands that HERS pay to the Company a sum to be determined at trial. On June 21, 2002, HERS filed a complaint in the same state court, asserting that Quovadx, Inc. and Healthcare.com have breached their performance obligations under the contract, and seeking damages in an amount to be determined at trial. The two lawsuits have been consolidated, discovery was initiated in July 2002, and no trial date has been set. In February 2003, The Company and HERS agreed to suspend the litigation pending the outcome of settlement discussions. In July 2003, the parties to the litigation reached a settlement agreement, but the settlement is subject to conditions. If the final settlement is not achieved, the Company intends to continue to prosecute its claims, and defend the claims brought by HERS, vigorously; however litigation is inherently uncertain and we can make no assurance as to the outcome or effect.

      The Company is engaged from time to time in routine litigation that arises in the ordinary course of our business.

20


Table of Contents

 
Item 2.      Changes in Securities and Use of Proceeds

      Not applicable.

 
Item 3.      Defaults Upon Senior Securities

      Not applicable.

 
Item 4.      Submission of Matters to a Vote of Security Holders

      We held our annual meeting of shareholders (the “Annual Meeting”) on June 19, 2003. The number of common votes present at the Annual Meeting with authority to vote and voting was 27,927,285 which represented 92% of the 30,196,425 common votes outstanding on April 21, 2003, the record date for the Annual Meeting. At the meeting, the following item relating to the Company was submitted to a vote of shareholders of the Company:

      Election of Class I Directors

                 
Votes For Votes Abstained


Fred L. Brown
    27,056,558       870,727  
Charles J. Roesslein
    27,052,134       875,151  

      Based on the voting results, these directors were elected to a three-year term.

 
Item 5.      Other Information

      Not applicable.

 
Item 6.      Exhibits and Reports on Form 8-K

      (a) Exhibits

        The exhibits listed in the accompanying Exhibit Index to this quarterly report on Form 10-Q are filed, furnished or incorporated by reference as part of this quarterly report.

      (b) Reports on Form 8-K

   (i) On April 23, 2003, we furnished a Current Report on Form 8-K to report that on April 23, 2003 we issued a press release announcing our financial results for the quarter ended March 31, 2003.
 
  (ii) On April 24, 2003, we furnished an amended Current Report on Form 8-K/A to report that on April 23, 2003 we reissued a press release announcing our financial results for the quarter ended March 31, 2003.

21


Table of Contents

SIGNATURES

      In accordance with the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereto duly authorized.

  QUOVADX, INC.

  By:  /s/ LORINE R. SWEENEY
 
  Lorine R. Sweeney
  President and Chief Executive Officer
  (Principal Executive Officer)

Date: August 4, 2003

  By:  /s/ GARY T. SCHERPING
 
  Gary T. Scherping
  Executive Vice President
  and Chief Financial Officer
  (Principal Financial and Accounting Officer)

Date: August 4, 2003

22


Table of Contents

EXHIBIT INDEX

             
Exhibit
Number Description of Document


  3 .1       Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Quarterly Report on Form 10-Q of the Registrant for the quarter ended March 31, 2003, filed as of May 13, 2003).
  3 .2       Bylaws of the Registrant (incorporated by reference to Exhibit 3.3 to the Registration Statement on Form S-1 filed by the Registrant as of November 2, 1999, Registration No. 333-90165).
  4 .1       Specimen stock certificate representing shares of Common Stock of the Registrant (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K of the Registrant, filed as of October 16, 2001).
  4 .2       Preferred Stock Rights Agreement, dated as of July 24, 2000, between the Registrant and ChaseMellon Shareholder Services, L.L.C., as Rights Agent, including the Certificate of Designation, the form of Rights Certificate and the Summary of Rights attached thereto as Exhibits A, B, and C, respectively (incorporated by reference to Exhibit 1 to the Registration Statement on Form 8-A filed by the Registrant as of July 28, 2000).
  4 .3       Registration Rights Agreement, dated as of December 14, 2001, between the Registrant and Francis Carden (incorporated by reference to Exhibit 4.1 to the Registration Statement on Form S-3 filed by the Registrant as of January 23, 2002, Registration No. 333-81210).
  10 .1*       Amended and Restated 1997 Stock Plan and related agreements (incorporated by reference to Exhibit 4.1 to the Registration Statement on Form S-8 filed by the Registrant as of May 16, 2002, Registration No. 333-88408).
  10 .2*       Amended and Restated 1999 Employee Stock Purchase Plan and related agreements (incorporated by reference to Exhibit 4.7 to the Registration Statement on Form S-8 filed by the Registrant as of April 1, 2003, Registration No. 333-104184).
  10 .3*       Amended and Restated 1999 Director Option Plan and related agreements (incorporated by reference to Exhibit 4.3 to the Registration Statement on Form S-8 filed by the Registrant as of May 16, 2002, Registration No. 333-88408).
  10 .4*       Amended and Restated 2000 Nonstatutory Stock Option Plan and related agreements (incorporated by reference to Exhibit 4.9 to the Registration Statement on Form S-8 filed by the Registrant as of April 1, 2003, Registration No. 333-104184).
  10 .5*       Amended and Restated Healthcare.com Corporation Non-Employee Director Stock Option Plan (filed as of August 13, 1999, as Exhibit 10 to the Quarterly Report on Form 10-Q of Healthcare.com Corporation for the quarter ended June 30, 1999, Commission File No. 0-27056, and incorporated by reference to Exhibit 10.42 to the Registration Statement on Form S-4 filed by the Registrant as of June 29, 2001, Registration No. 333-64282).
  10 .6*       Healthcare.com Corporation Adjustment Stock Option Plan (filed as of October 24, 1995, as Exhibit 10.5 to Amendment No. 1 to the Registration Statement on Form S-1 of Healthcare.com Corporation, Registration No. 33-96478, and incorporated by reference to Exhibit 10.43 to the Registration Statement on Form S-4 filed by the Registrant as of June 29, 2001, Registration No. 333-64282).
  10 .7*       Healthcare.com Corporation Restated Stock Option Plan Two (filed as of May 11, 1998, as Exhibit 10.2 to the Quarterly Report on Form 10-Q of Healthcare.com Corporation for the quarter ended March 31, 1998, Commission File No. 0-27056, and incorporated by reference to Exhibit 10.44 to the Registration Statement on Form S-4 filed by the Registrant as of June 29, 2001, Registration No. 333-64282).
  10 .8*       Offer letter, dated as of February 20, 2002, with David E. Nesvisky (incorporated by reference to Exhibit 10.8 to the Annual Report on Form 10-K of the Registrant for the year ended December 31, 2002, filed as of March 31, 2003).
  10 .9       Office Lease Agreement, effective as of November 8, 1999, between Mountain States Mutual Casualty Company and the Registrant (incorporated by reference to Amendment 1 to the Registration Statement on Form S-1 filed by the Registrant as of December 17, 1999, Registration No. 333-90165).


Table of Contents

             
Exhibit
Number Description of Document


  10 .10       Sublease, dated as of August 24, 2001, between Echo Bay Management Corp. and XCare.net, Inc. (incorporated by reference to Exhibit 12.1 to the Annual Report on Form 10-K of the Registrant for the year ended December 31, 2001, filed as of March 26, 2002).
  10 .11*       Form of Healthcare.com Corporation Severance Compensation and Restrictive Covenant Agreement and form of Severance Compensation and Restrictive Covenant Agreement between Healthcare.com Corporation and Deborah Dean dated May 14, 2001 (incorporated by reference to Exhibit 2.6 to the Current Report on Form 8-K of the Registrant, filed as of May 18, 2001).
  10 .12       Form of Indemnification Agreement entered into by Quovadx, Inc. with each of its directors and executive officers (incorporated by reference to Exhibit 11.1 to the Annual Report on Form 10-K of the Company for the year ended December 31, 2001, filed as of March 26, 2002, Commission File No. 000-29273).
  31 .1       Certification of Chief Executive Officer of the Registrant pursuant to Rule 13a-14(a) and Rule 15d-14(a), promulgated under the Securities Exchange Act of 1934, as amended.
  31 .2       Certification of Chief Financial Officer of the Registrant pursuant to Rule 13a-14(a) and Rule 15d-14(a), promulgated under the Securities Exchange Act of 1934, as amended.
  32 .1**       Certification of Chief Executive Officer of the Registrant pursuant to Rule 13a-14(b) and Rule 15d-14(b), promulgated under the Securities Exchange Act of 1934, as amended, and 18 U.S.C. §1350.
  32 .2**       Certification of Chief Financial Officer of the Registrant pursuant to Rule 13a-14(b) and Rule 15d-14(b), promulgated under the Securities Exchange Act of 1934, as amended, and 18 U.S.C. §1350.


  *  Constitutes a management contract or compensatory plan or arrangement.

**  This certification is furnished to, but not filed, with the Commission. This certification shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except to the extent that the Registrant specifically incorporates it by reference.